Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Common Equity: 2021-2025

Historic Common Equity for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $11.6 million.

  • InMed Pharmaceuticals' Common Equity rose 38.06% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 38.06%. This contributed to the annual value of $13.4 million for FY2025, which is 45.93% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Common Equity of $11.6 million as of Q3 2025, which was down 13.72% from $13.4 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Common Equity high stood at $15.2 million for Q3 2021, and its period low was -$9.6 million during Q3 2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Common Equity value was $11.1 million (recorded in 2024), while the average stood at $8.6 million.
  • In the last 5 years, InMed Pharmaceuticals' Common Equity plummeted by 187.01% in 2023 and then skyrocketed by 187.65% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Common Equity (Quarterly) stood at $14.2 million in 2021, then rose by 1.18% to $14.3 million in 2022, then dropped by 10.90% to $12.8 million in 2023, then crashed by 51.60% to $6.2 million in 2024, then spiked by 38.06% to $11.6 million in 2025.
  • Its Common Equity stands at $11.6 million for Q3 2025, versus $13.4 million for Q2 2025 and $7.0 million for Q1 2025.